Literature DB >> 26581613

Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.

Wai Kien Yip1, Pei Yuan He1,2, Maizaton Atmadini Abdullah1, Suryati Yusoff3, Heng Fong Seow4,5.   

Abstract

Molecular alterations in PIK3CA oncogene that encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K p110α) are commonly found in human cancers. In this study, we examined the expression of PI3K p110α and PIK3CA gene amplification in 74 nasopharyngeal carcinoma (NPC) cases. Immunohistochemical staining demonstrated overexpression of PI3K p110α protein in 44.6% (33/74) of NPCs and 4.8% (2/42) of the adjacent normal nasopharyngeal mucosa. Copy number of PIK3CA gene was successfully analyzed in 51 of the total NPC cases and 19 non-malignant nasopharynx tissues by quantitative real-time PCR. Using mean + 2(standard deviation) of copy numbers in the non-malignant nasopharynx tissues as a cutoff value, PIK3CA copy number gain was found in 10 of 51 (19.6%) NPC cases. High PI3K p110α expression level was correlated with increased PIK3CA copy number (Spearman's rho =0.324, P = 0.02). PI3K p110α expression and PIK3CA copy number did not associate with Akt phosphorylation, and patient and tumor variables. This study suggests that PI3K p110α overexpression, which is attributed, at least in part, to PIK3CA gene amplification, may contribute to NPC pathogenesis. However, these molecular aberrations may not be responsible for activation of Akt signaling in NPC.

Entities:  

Keywords:  Akt; Immunohistochemistry; Nasopharyngeal carcinoma; PIK3CA

Mesh:

Substances:

Year:  2015        PMID: 26581613     DOI: 10.1007/s12253-015-0007-8

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  36 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Activation of phosphatidylinositol 3-kinase/Akt signaling by EGF downregulates membranous E-cadherin and β-catenin and enhances invasion in nasopharyngeal carcinoma cells.

Authors:  Wai Kien Yip; Heng Fong Seow
Journal:  Cancer Lett       Date:  2011-12-17       Impact factor: 8.679

3.  Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.

Authors:  Peng Hou; Dingxie Liu; Yuan Shan; Shuiying Hu; Kimberley Studeman; Stephen Condouris; Yangang Wang; Ariel Trink; Adel K El-Naggar; Giovanni Tallini; Vasily Vasko; Mingzhao Xing
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

4.  Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.

Authors:  Yong Lin; Xiaofei Jiang; Ye Shen; Min Li; Huili Ma; Mingzhao Xing; Yuan Lu
Journal:  Endocr Relat Cancer       Date:  2008-10-13       Impact factor: 5.678

5.  Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma.

Authors:  Wai Kien Yip; Vincent Ching Shian Leong; Maizaton Atmadini Abdullah; Suryati Yusoff; Heng Fong Seow
Journal:  Oncol Rep       Date:  2008-02       Impact factor: 3.906

6.  PIK3CA alterations in Middle Eastern ovarian cancers.

Authors:  Jehad Abubaker; Prashant Bavi; Wael Al-Haqawi; Zeenath Jehan; Adnan Munkarah; Shahab Uddin; Khawla S Al-Kuraya
Journal:  Mol Cancer       Date:  2009-07-28       Impact factor: 27.401

7.  Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.

Authors:  Zeenath Jehan; Prashant Bavi; Mehar Sultana; Jehad Abubaker; Rong Bu; Azhar Hussain; Ghazi Alsbeih; Nasser Al-Sanea; Alaa Abduljabbar; Luai H Ashari; Samar Alhomoud; Fouad Al-Dayel; Shahab Uddin; Khawla S Al-Kuraya
Journal:  J Pathol       Date:  2009-11       Impact factor: 7.996

8.  PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival.

Authors:  Chu-Chung Chou; Ming-Jen Chou; Chin-Yuan Tzen
Journal:  Med Oncol       Date:  2008-11-15       Impact factor: 3.064

9.  PIK3CA is implicated as an oncogene in ovarian cancer.

Authors:  L Shayesteh; Y Lu; W L Kuo; R Baldocchi; T Godfrey; C Collins; D Pinkel; B Powell; G B Mills; J W Gray
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

10.  KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.

Authors:  Chen Mao; Junhua Zhou; Zuyao Yang; Yafang Huang; Xinyin Wu; Hong Shen; Jinling Tang; Qing Chen
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

View more
  3 in total

1.  Meta-signature of mutated genes in gallbladder cancer: evidence based high throughput screening assays.

Authors:  Kai Qu; Xing Zhang; Ruixia Cui; Chang Liu
Journal:  Ann Transl Med       Date:  2016-06

2.  Relationship Between PIK3CA Amplification and P110α and CD34 Tissue Expression as Angiogenesis Markers in Iranian Women with Sporadic Breast Cancer.

Authors:  Shadi Hosseini; Farkhondeh Behjati; Maryam Rahimi; Nazanin Taheri; Hamidreza Khoram Khorshid; Fatemeh Aghakhani Moghaddam; Saghar Ghasemi; Masoud Karimlou; Fereidoon Sirati; Elahe Keyhani
Journal:  Iran J Pathol       Date:  2018-09-25

3.  Serum- and glucocorticoid-inducible kinase 3 is a potential oncogene in nasopharyngeal carcinoma.

Authors:  Jing Chen; Hai Liang Li; Bo Bo Li; Wei Li; Dong Ma; Yong He Li; Tao Liu
Journal:  Braz J Otorhinolaryngol       Date:  2018-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.